2024
1140-P: Impact of Empagliflozin on Hyperfiltration in Youth with Type 2 Diabetes—Post Hoc Analysis of the DINAMO and DINAMO MONO Trials
BJORNSTAD P, DANNE T, TAMBORLANE W, KLINGENSMITH G, SCHUELER E, TARTAKOVSKY I, MARQUARD J, ZEITLER P, WILLI S, LAFFEL L. 1140-P: Impact of Empagliflozin on Hyperfiltration in Youth with Type 2 Diabetes—Post Hoc Analysis of the DINAMO and DINAMO MONO Trials. Diabetes 2024, 73 DOI: 10.2337/db24-1140-p.Peer-Reviewed Original ResearchDiabetic kidney diseaseKidney diseaseHoc analysisDiabetic kidney disease riskEarly diabetic kidney diseaseBaseline to weekImpact of empagliflozinCystatin C equationClinically relevant improvementNational Institute of DiabetesDigestive and Kidney DiseasesPost hoc analysisEGFR changeIncreased riskHyperfiltrationPubertal statusGlycemic controlEGFRC equationLong-term effectsPotential long-term effectsRelevant improvementNormofiltrationT2DHealthy youth
2022
Youth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study
Wolf RM, Cheng P, Gal RL, Beaulieu LC, Kollman C, Isganaitis E, Magge S, Mastrandrea LD, Klingensmith GJ, Tamborlane W, Van Name M, Consortium P. Youth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study. Pediatric Diabetes 2022, 23: 439-446. PMID: 35138021, DOI: 10.1111/pedi.13325.Peer-Reviewed Original ResearchConceptsIntensive lifestyle interventionTreatment failureType 2 diabetesDiabetes medicationsLifestyle interventionGlycemic controlDiscontinuation of insulinExperienced treatment failureInitial insulin treatmentYouth-onset T2DHigh rateMetformin monotherapyPrimary outcomeMedian timeRisk factorsInsulin treatmentMetforminProgressive natureConsortium studyLogistic regressionInsulinT2DIntensive lifestyleMedicationsDiabetes
2018
The present and future treatment of pediatric type 2 diabetes
Van Name MA, Guandalini C, Steffen A, Patel A, Tamborlane W. The present and future treatment of pediatric type 2 diabetes. Expert Review Of Endocrinology & Metabolism 2018, 13: 207-212. PMID: 30063424, DOI: 10.1080/17446651.2018.1499467.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesPediatric type 2 diabetesStandard initial treatmentMetformin monotherapyPediatric T2DClinical outcomesInitial treatmentPediatric populationClinical trialsRapid progressionInjectable agentsFuture treatmentMetabolic controlT2DDiabetesNew drugsInsulinPhase 3DrugsRegulatory approvalT2D.TreatmentPatientsMetforminCurrent use
2017
Predictors of Loss to Follow-Up among Children with Type 2 Diabetes
Shoemaker A, Cheng P, Gal RL, Kollman C, Tamborlane WV, Klingensmith GJ, Clements MA, Hannon TS, Heptulla R, Less J, Wood J. Predictors of Loss to Follow-Up among Children with Type 2 Diabetes. Hormone Research In Paediatrics 2017, 87: 377-384. PMID: 28505610, DOI: 10.1159/000475595.Peer-Reviewed Original ResearchConceptsType 2 diabetesMultivariable logistic regression modelPediatric diabetes centersPredictors of lossLogistic regression modelsRace/ethnicityClinical factorsDiabetes CenterPoor complianceOdds ratioMedical careEnrollment variablesSignificant predictorsSocioeconomic factorsOlder adolescentsT2DDiabetesPatientsClinicCareRegression modelsParent educationPredictorsYearsFinal modelUnderstanding bolus insulin dose timing: the characteristics and experiences of people with diabetes who take bolus insulin
Tamborlane WV, Pfeiffer KM, Brod M, Nikolajsen A, Sandberg A, Peters AL, Van Name M. Understanding bolus insulin dose timing: the characteristics and experiences of people with diabetes who take bolus insulin. Current Medical Research And Opinion 2017, 33: 639-645. PMID: 28008782, DOI: 10.1080/03007995.2016.1275937.Peer-Reviewed Original ResearchConceptsBolus insulinDose timingBolus insulin therapyPrevious weekType 2 diabetesExperiences of peopleInsulin therapyTreatment optionsDiabetes educationWeb-based surveyType 1DiabetesMajority of respondentsInsulinSelf-report surveyGeneralizability of findingsT2DT1DMealWeeksHypoglycemiaRespondentsTherapyBolusPotential bias
2016
A cross‐sectional view of the current state of treatment of youth with type 2 diabetes in the USA: enrollment data from the Pediatric Diabetes Consortium Type 2 Diabetes Registry
Nambam B, Silverstein J, Cheng P, Ruedy KJ, Beck RW, Wadwa R, Klingensmith G, Willi SM, Wood JR, Bacha F, Thomas IH, Tamborlane WV, Consortium F. A cross‐sectional view of the current state of treatment of youth with type 2 diabetes in the USA: enrollment data from the Pediatric Diabetes Consortium Type 2 Diabetes Registry. Pediatric Diabetes 2016, 18: 222-229. PMID: 26970319, DOI: 10.1111/pedi.12377.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdolescentAdultChildCohort StudiesCombined Modality TherapyComorbidityCross-Sectional StudiesDiabetes Mellitus, Type 2Glycated HemoglobinHumansHyperglycemiaHypoglycemiaMedical RecordsPractice Patterns, Physicians'PrevalenceRegistriesRisk FactorsUnited StatesYoung Adult
2015
C‐peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry
Gregg B, Connor CG, Cheng P, Ruedy KJ, Beck RW, Kollman C, Schatz D, Cengiz E, Tamborlane WV, Klingensmith GJ, Lee JM, Consortium F. C‐peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes 2015, 17: 274-280. PMID: 25940861, DOI: 10.1111/pedi.12280.Peer-Reviewed Original ResearchConceptsC-peptide levelsC-peptide measurementsLower body mass indexPediatric type 2 diabetesInsulin-treated patientsEndogenous insulin secretionPediatric diabetes centersC-peptide valuesBody mass indexType 2 diabetesT2D durationInsulin therapyClinical factorsDiabetes CenterClinic registryMass indexC-peptideInsulin secretionInsulin treatmentLarge cohortT2DMetabolic controlType 2Biologic dataRegistry